Work in our laboratory is trying to identify new and effective ways to protect motor neurons (and other affected cells and tissues of the body) against disease in both childhood and adult forms of MND. A lot of our focus is currently on spinal muscular atrophy (SMA), where we are using both drug-based and gene therapy-based approaches to target key disease pathways. In particular, we are focussing on so-called ‘combinatorial therapies’ where you bring together multiple treatments in order to get maximum clinical benefit. We are also exploring how therapies developed for SMA may be applicable to help patients with ALS.
Developing new therapies for motor neuron disease (SMA and ALS)
About the project
Funder(s)
Publication(s)
Advances in therapy for spinal muscular atrophy: promises and challenges
Nat Rev Neurol. 2018 Apr;14(4):214-224
In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology
Cell Rep. 2017 Oct 24;21(4):953-965
Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy
J Clin Invest. 2014 Apr;124(4):1821-34
DOI: 10.1172/JCI71318
Dynamic modulation of the motor neuron translatome during developmental synapse elimination
Science Signaling 2025 Apr 15
Primary location
Principal Investigator
Other people involved
Dr Ewout Groen Dr Helena Chaytow Dr Nikky Huang Dr Kiterie Faller Ines Boehm Leire Ledahawsky Dinja van der Hoorn
Other people involved
Dr Ewout Groen Dr Helena Chaytow Dr Nikky Huang Dr Kiterie Faller Ines Boehm Leire Ledahawsky Dinja van der Hoorn
